GlassScriptPhysician profile
Kris Helphinstine
NPI 1053683375
$3,333.08
in general payments reported to CMS, 2019-2025
23 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $814 · 2024: $1,396 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,309 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,308.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $611.84 | 2023-2025 | |
| Lilly USA, LLC | $503.48 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $345.62 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.40 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $232.53 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $230.20 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $185.88 | 2023-2025 | |
| Corcept Therapeutics | $140.15 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $134.63 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $112.92 | 2023-2025 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $112.50 | 2024-2025 | Rexulti |
| Amgen INC. | $95.12 | 2023-2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $86.02 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $59.00 | 2024-2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Exact Sciences Corporation | $46.02 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $27.23 | 2025 | |
| Medicure Pharma INC. | $24.25 | 2024 | Zypitamag |
| Daiichi Sankyo INC. | $24.19 | 2024 | Injectafer |
| Philips North America LLC | $24.04 | 2024 | (Ck4) Mcot |
| Janssen Pharmaceuticals, INC | $20.33 | 2024 | Spravato |
| Impulse Dynamics (USA) INC. | $19.31 | 2023 | Optimizer |
| Kowa Pharmaceuticals America, INC. | $18.73 | 2025 | Zoryve |
| Organon LLC | $8.69 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kris Helphinstine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.